Longitudinal, leakage corrected and uncorrected rCBV during the first-line treatment of glioblastoma: a prospective study

2019 ◽  
Vol 144 (2) ◽  
pp. 409-417 ◽  
Author(s):  
Eike Steidl ◽  
Mathias Müller ◽  
Andreas Müller ◽  
Ulrich Herrlinger ◽  
Elke Hattingen
2005 ◽  
Vol 19 (1) ◽  
pp. 11-14 ◽  
Author(s):  
A. Skolarikos ◽  
E. Alargof ◽  
A. Rigas ◽  
Ch. Deliveliotis ◽  
E. Konstantinidis

2017 ◽  
Vol 12 (1) ◽  
pp. 24 ◽  
Author(s):  
Giovanna Vitaliti ◽  
Raffaele Falsaperla ◽  
Laura Mauceri ◽  
Catia Romano ◽  
Piero Pavone ◽  
...  

2014 ◽  
Vol 60 (3) ◽  
pp. 106-108 ◽  
Author(s):  
Nona-Aura Florincescu-Gheorghe ◽  
Florica Popescu ◽  
D.O. Alexandru

Abstract Introduction: Allergic rhinitis is one of the most common allergic diseases, characterized by the inflammation of the nasal mucosa. Eosinophils play a predominant pro-inflammatory role in allergic inflammation. This study assesses the effect of mometasone furoate alone or in combination with desloratadine/montelukast in patients with moderate-severe allergic rhinitis. Material and method: This is a prospective study that took place over 8 weeks on 70 patients diagnosed with moderate-severe allergic rhinitis with sensitization to the pollen of Ambrosia elatior. The patients were evaluated on the basis of their symptoms using the total score of nasal symptoms, the score of individual nasal symptoms and the number of eosinophils in the nasal secretion. Results: All 3 groups of patients had an improvement on the total nasal symptoms score. However, the combination of mometasone furoate with desloratadine provided statistically significant benefits on the total score of symptoms and on nasal itching as compared with mometasone furoate alone. Conclusions: The association of mometasone furoate with desloratadine should be considered first-line treatment of moderate-severe allergic rhinitis due to the benefit both on the total symptom score and on of nasal itching.


Sign in / Sign up

Export Citation Format

Share Document